Until recently, cannabis has mainly been known as a psychotropic and psychoactive substance. The use of cannabis for medicinal purposes has its origins in antiquity. In the 50s, the first studies conducted on cannabinoids showed its anti-tumor properties. Nowadays, cannabis is officially recognized in some US states as a pain reliever that increases appetites and reduces sleeplessness in cancer patients.
Effective immediately we can enroll selected patients in a clinical phase 1 study with dexanabinol, a form of synthetic cannabis, in the treat of tumor disease. UNIFONTIS will act as the leader of the study. It is not actual cannabis, but a synthetic variant that be intravenously administered, and will be given in tandem with chemotherapy and alone as a therapy against cancer.
I would be glad to personally consult with you the benefits, opportunities, and risks of this therapy. We are looking forward to being able to support you in any way possible. International patients welcome! We speak English.
UNIFONTIS | Prof. Dr. med. Joachim Drevs
Specialist for internal medicine
Additional qualification in hematology / private oncology doctor
Fax: +49 (0)5305-1317
Central contact number:
© Copyright UNIFONTIS. Alle Rechte vorbehalten.